transforming-growth-factor-beta and Angiomyolipoma

transforming-growth-factor-beta has been researched along with Angiomyolipoma* in 1 studies

Other Studies

1 other study(ies) available for transforming-growth-factor-beta and Angiomyolipoma

Article	Year
Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target EMBO molecular medicine, 2017, Volume: 9, Issue:4 Angiomyolipoma (AML), the most common benign renal tumor, can result in severe morbidity from hemorrhage and renal failure. While mTORC1 activation is involved in its growth, mTORC1 inhibitors fail to eradicate AML, highlighting the need for new therapies. Moreover, the identity of the AML cell of origin is obscure. AML research, however, is hampered by the lack of Topics: Angiomyolipoma; Animals; Cell Line, Tumor; Connective Tissue Growth Factor; Gene Expression Profiling; Humans; Mesenchymal Stem Cells; Mice; PPAR gamma; Proto-Oncogene Proteins c-sis; Therapeutics; Transforming Growth Factor beta	2017

Article

Year

Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target

EMBO molecular medicine, 2017, Volume: 9, Issue:4

Angiomyolipoma (AML), the most common benign renal tumor, can result in severe morbidity from hemorrhage and renal failure. While mTORC1 activation is involved in its growth, mTORC1 inhibitors fail to eradicate AML, highlighting the need for new therapies. Moreover, the identity of the AML cell of origin is obscure. AML research, however, is hampered by the lack of

Topics: Angiomyolipoma; Animals; Cell Line, Tumor; Connective Tissue Growth Factor; Gene Expression Profiling; Humans; Mesenchymal Stem Cells; Mice; PPAR gamma; Proto-Oncogene Proteins c-sis; Therapeutics; Transforming Growth Factor beta

2017